newsfilter
← Earnings
Earnings Releases·

Indivior — Third Quarter 2026 Earnings Summary

Indivior reported third-quarter 2026 total net revenue of $356 million, a 13% increase year-over-year, driven by a record $267 million in SUBLOCADE net revenue. The company achieved record quarterly net income of $137 million and adjusted EBITDA of $211 million, with margins expanding significantly compared to the prior year. Indivior remains on track to close its all-stock merger with Supernus on November 2, 2026, at which point the combined entity will operate as Supernus, Inc. under the ticker symbol SUPN. Full-year 2026 financial guidance for the standalone organization projects net revenue between $1.295 billion and $1.365 billion and adjusted EBITDA between $700 million and $740 million.

Company
INDIVIOR PHARMACEUTICALS INC
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic